KMB — Q3 2026 Financial Report Analysis

Kimberly-Clark (the maker of Huggies, Kleenex, Cottonelle and Depend) released preliminary, unaudited estimates for its third quarter of 2026 (July 1 – September 30, 2026) on October 15, three weeks before its full results, which are scheduled for November 5. The figures are the company's own estimates, its auditor has not reviewed them, and they may still change. Underneath, the business shrank: organic sales fell 1.3%, and adjusted operating profit slipped 0.9% to $677 million. Adjusted EPS from continuing operations still rose 17% to $1.70, but about half of that rise came from a much lower tax rate, not from selling more. Reported (GAAP) EPS of $5.37 is inflated by a one-time $4.33-per-share gain on the tissue joint venture with Suzano that closed on July 1. Management kept its full-year outlook unchanged.

At a glance

• Organic sales -1.3% (vs. +2.5% a year ago): the underlying business sold less than last year, even though its markets are still growing about 1.7% a year, by the company's own measure.
• Adjusted EPS from continuing operations +17.2% to $1.70: the adjusted tax rate fell to 19.5% from 26.5%, and on our math that alone accounts for about $0.13 of the $0.25 increase. Adjusted operating profit fell.
• Reported EPS $5.37 vs. $1.34: $4.33 of it is the one-time gain from handing 51% of the international tissue business to Suzano. The cash that sale brought in is why cash on hand rose to $1,874 million from $617 million.

What this filing is (and isn't)

This is not the usual earnings release. It is an 8-K (a short SEC filing for material news) giving a small set of estimated figures for the quarter, with a note that "consolidated financial statements are not available" yet. There is no segment breakdown, no volume vs. price split, no cash-flow statement and no management commentary explaining why sales fell. Those will come with the full release on November 5 and the 10-Q. So this report covers what the estimates show, and we will update it once the full filing is out.

As in Q2, the figures for sales and operating profit cover only the continuing business (North America and International Personal Care). The former international tissue and professional-products business (IFP) moved on July 1 into Arbex, a joint venture that is 51% owned by Suzano and 49% by Kimberly-Clark. From this quarter on, Kimberly-Clark's share of Arbex's profit shows up as "equity income", one line below operating profit, not in sales.

Key figures

Margins are our calculations from the estimated dollar figures. Organic sales growth strips out currency swings and businesses the company has exited, to show how much the ongoing business actually grew. Gross margin is the share of sales left after the cost of making the products; operating margin is the share left after also paying for marketing, research and overhead, before interest and tax. "Adjusted" figures are the company's own non-GAAP measures, which leave out restructuring, deal costs and other items it treats as one-offs. The filing does not give a net income figure for the quarter, only per-share amounts.

Sales: the underlying business shrank

Reported net sales slipped 0.4% to $4,134 million, but organic sales fell 1.3%. That means currency and business-exit effects made the reported number look about 0.9 points better than the underlying trend. The year-ago quarter is a tough comparison (organic +2.5%), but the more telling benchmark is the company's own: it says its categories (the diaper, tissue and personal-care markets where it competes, weighted by its exposure) are growing about 1.7% on a trailing 12-month basis. A -1.3% result means Kimberly-Clark grew about 3 points slower than its markets this quarter, which implies it lost market share.

The filing does not say why. In Q2, the 10-Q blamed North America on retailers cutting inventories and a fire at its Los Angeles distribution center, and International Personal Care on false social-media allegations about its diaper brands in China. Whether those factors got better or worse in Q3 will only be clear on November 5.

Profit: tax and joint-venture income did the lifting

Adjusted gross margin fell 130 bps to 35.5%. The filing doesn't explain why, but Q2's margin had been lifted by one-time tariff refunds, which makes a step down plausible. Adjusted operating profit was nearly flat at $677 million (-0.9%), so the adjusted operating margin barely moved (16.4% vs. 16.5%): overhead savings roughly made up for lost gross profit.

The 17% rise in adjusted EPS from continuing operations came from below operating profit. Using the company's own reconciliation tables (our arithmetic):

• Tax: adjusted pre-tax income rose 3.9% to $632 million, but adjusted tax fell to $123 million from $161 million as the adjusted rate dropped to 19.5% from 26.5%. At last year's rate, this year's tax bill would have been about $44 million higher, or about $0.13 per share. That is roughly half of the $0.25 EPS increase. The filing doesn't say whether this lower rate will last.
• Below-the-line items: adjusted pre-tax income rose by $24 million even though adjusted operating profit fell by $6 million, so net interest and other non-operating items improved by about $30 million. The filing doesn't break this down. Cash on hand was more than three times last year's level after the Suzano proceeds came in, which may have helped.
• Equity income: the gap between after-tax income and the adjusted EPS total implies roughly $58 million from partly owned companies (net of minority interests), up from roughly $36 million. This is where Kimberly-Clark's 49% of Arbex now shows up. The figure also excludes $0.12 per share of Arbex's own deal-accounting and restructuring charges ("equity company adjustments").
• Share count was essentially flat (333.7 million vs. 333.1 million diluted shares), so buybacks contributed nothing.

Takeaway: The 17% jump in adjusted EPS is not a sign of a healthier business. Organic sales fell 1.3% while Kimberly-Clark's markets grew about 1.7%, and adjusted operating profit dipped. Roughly half of the EPS gain came from a 7-point drop in the adjusted tax rate. The rest came from lower interest and other costs plus new income from the Arbex joint venture. For now, the company is earning more per share while selling less.

What the headline numbers hide

• The $5.37 reported EPS is mostly a one-time gain. $4.33 of it is the "IFP Transaction Gain" from selling 51% of the tissue business into Arbex. At 333.7 million shares, that is about $1.4 billion (our calculation). It will not recur.
• GAAP operating profit fell 17%, mostly because of deal costs. The $161 million gap between reported operating profit ($516M) and adjusted ($677M) is mainly $106 million of costs for the pending Kenvue acquisition (advisory, legal and accounting fees) plus $55 million of restructuring under the 2024 Transformation Initiative. Kenvue costs were $109 million in Q2 as well, so they are recurring every quarter until the deal closes, even though they are excluded from adjusted figures.
• Last year's tax rate was distorted, which flatters the comparison for GAAP EPS. The reported tax rate a year ago was 45.4%, inflated by a $96 million charge tied to the 2025 US tax law (OBBBA) that wrote down foreign tax credits. That is a big part of why GAAP EPS from continuing operations looks up 17.8% even though GAAP operating profit fell 17%.
• On a like-for-like "whole company" basis, adjusted EPS fell 6.6% ($1.70 vs. $1.82). Last year's figure included all of the tissue business's profits; this year Kimberly-Clark keeps only its 49% share through Arbex, and it received cash for the rest. This is the dilution the company guided to.
• No cash-flow data yet. The preliminary filing gives no operating cash flow, so we can't check whether profits turned into cash this quarter. First-half operating cash flow was strong ($1,653 million vs. $1,097 million), mostly because of a working-capital inflow.

Did last time's read hold up?

After Q2, we said the full-year target needed a stronger second half while China stayed a drag, and listed three things to watch: a North American volume recovery, a China diaper recovery and the Kenvue closing. EPS did speed up (adjusted EPS from continuing operations grew 17% in Q3 vs. 10% in Q2), but through tax and equity income, not sales. Organic sales got worse, from -0.1% to -1.3%, so there's no sign yet of the volume recovery. The company still attributes about 1 point of full-year drag to China, unchanged from August. Kenvue is still pending.

Outlook

Management said its 2026 outlook "remains consistent with previous expectations":

• Organic sales growth about 1 point below the growth of its categories, with about 1 point of total-company drag from the China social-media disruption. Category growth is now about 1.7% (it was about 2% in August).
• Adjusted operating profit up mid-single digits in constant currency (excluding exchange-rate moves).
• Adjusted EPS from continuing operations up high-single digits in constant currency.
• Adjusted EPS attributable to Kimberly-Clark (including the tissue business it partly gave up) down low-single digits in constant currency.

The outlook excludes the Kenvue acquisition.

Our read: the EPS targets look reachable because the tax rate and Arbex income are doing more of the work than in the first half. The operating targets look harder. Adjusted operating profit fell 0.9% in Q3 after rising 6.2% in Q2. The sales target ("about 1 point below" categories growing about 1.7%, so roughly +0.7%) is also hard to square with Q2 at -0.1% and Q3 at -1.3%. Unless Q1 was much stronger than we can see from this filing, Q4 would need a sharp recovery. On November 5, look for three things: the North America vs. International split and volume vs. price; whether the 19.5% adjusted tax rate is a one-off or the new normal; and any update on the Kenvue closing, which would add about 280 million shares and about $6.7 billion of cash consideration and make 2027 results hard to compare with today's.